Cell Medica’s £60 million Series C investment round

Cell Medica, a leading cellular immunotherapy company, has closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

This content is for Standard 1 Year members only.
Login Join Now